Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease.
Paula BarrerasEleni S VasileiouAngeliki G FilippatouKathryn C FitzgeraldMichael LevyCarlos A Pardo-VillamizarScott D NewsomeEllen M MowryPeter A CalabresiElias S SotirchosPublished in: Neurology (2022)
This study provides Class IV evidence that rituximab decreases the annualized relapse rate in AQP4-IgG-seropositive NMOSD and MOGAD.